TrialJournal of the European Academy of Dermatology and Venereology : JEADV2021

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.

A S Paller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.